Generation Bio Announces Merger with XOMA Royalty

Generation Bio ( (GBIO) ) just unveiled an update.

On December 15, 2025, Generation Bio Co. entered into a merger agreement with XOMA Royalty Corporation, under which XOMA will acquire all outstanding shares of Generation Bio for $4.2913 per share in cash, along with a contingent value right (CVR) for potential future payments. The merger, expected to close in February 2026, will see Generation Bio become a wholly owned subsidiary of XOMA, enhancing XOMA’s portfolio with Generation Bio’s ctLNP delivery platform. The merger agreement includes conditions such as the tender of a majority of shares and customary closing conditions, with support agreements from stockholders holding approximately 15% of Generation Bio’s shares.

The most recent analyst rating on (GBIO) stock is a Sell with a $4.50 price target. To see the full list of analyst forecasts on Generation Bio stock, see the GBIO Stock Forecast page.

Spark’s Take on GBIO Stock

According to Spark, TipRanks’ AI Analyst, GBIO is a Underperform.

Generation Bio’s stock score is primarily impacted by its poor financial performance, characterized by declining revenues, high leverage, and negative cash flows. Technical analysis indicates bearish momentum, and the valuation is unattractive due to a negative P/E ratio and lack of dividend yield. These factors contribute to a low overall stock score.

To see Spark’s full report on GBIO stock, click here.

More about Generation Bio

Generation Bio is a biotechnology company focused on developing therapies for T cell-driven autoimmune diseases using cell-targeted lipid nanoparticles (ctLNP) to deliver small interfering RNA (siRNA) to T cells.

Average Trading Volume: 56,344

Technical Sentiment Signal: Sell

Current Market Cap: $36.59M

For a thorough assessment of GBIO stock, go to TipRanks’ Stock Analysis page.